Le Lézard
Classified in: Health, Covid-19 virus
Subject: MRR

USD 3.89 Bn Growth in Genome Engineering Market | 17,000+ Technavio Research Reports

NEW YORK, Nov. 29, 2021 /PRNewswire/ -- The "Genome Engineering Market by Technology and Geography - Forecast and Analysis 2021-2025" report has been added to Technavio's offering. With ISO 9001:2015 certification, Technavio is proudly partnering with more than 100 Fortune 500 companies for over 16 years.


The potential growth difference for the genome engineering market between 2020 and 2025 is USD 3.89  billion. To get the exact yearly growth variance and the Y-O-Y growth rate, Talk to our analyst.

Key Market Dynamics:

The increasing applications of genome engineering in therapeutics and the increase in human genomics research are some of the key market drivers. The prevalence of chronic and infectious diseases such as malaria, tuberculosis, HIV/AIDS, and hepatitis has increased rapidly. The outbreak of COVID-19 has also surged the demand for vaccine development. Researchers are working on new gene-based therapies to reduce morbidity and mortality among HIV-infected patients. Genome engineering can provide therapeutic tools for this disease. 

However, factors such as ethical issues and adverse public perception will challenge market growth. The benefits of genetic engineering may be far-reaching, and the impacts are not entirely known. When GMOs are released into the environment, they cannot be removed, and it may take centuries or decades to fully realize the consequences. The impact can affect the entire world and may not be restricted to those that created the organisms. 

To learn about additional key drivers, trends, and challenges available with TechnavioRead our FREE Sample Report!

The genome engineering market report is segmented by Technology (CRISPR, TALEN, ZFN, and others) and Geography (North America, Europe, Asia, and ROW).  CRISPR technology segment led the market share in 2020 and will continue to dominate the market during the forecast period. CRISPR is a segment of prokaryotic DNA that contains short base sequence repetition. It is widely used to efficiently modify genes that are difficult to manipulate genetically in traditional ways. The low cost of this revolutionized technology has made it a perfect option for end-users such as pharmaceutical and biotechnology companies, government and academic research institutes, and contract research organizations. 

In terms of geography, North America will be the leading region with 40% of the market's growth during the forecast period. The increase in funding for genomic R&D in precision medicine and personalized therapies drives the demand for genomic analyses in North America. The US is the key market for genome engineering in North America. The country is the first and the largest producer of genetically modified organisms (GMOs) in the world.    

View our sample report for additional insights into the contribution of all the segments, and regional opportunities in the report.

Some Companies Mentioned  

Related Reports:

Genome Editing Market by End-user and Geography - Forecast and Analysis 2020-2024

Synthetic Biology Market by Application and Geography - Forecast and Analysis 2020-2024

Genome Engineering Market Scope

Report Coverage


Page number


Base year


Forecast period


Growth momentum & CAGR

Accelerate at a CAGR of 14.45%

Market growth 2021-2025

$ 3.89 billion

Market structure


YoY growth (%)


Regional analysis

North America, Europe, Asia, and ROW

Performing market contribution

North America at 40%

Key consumer countries

US, Germany, Canada, UK, China, and France

Competitive landscape

Leading companies, competitive strategies, consumer engagement scope

Companies profiled

CRISPR Therapeutics AG, Danaher Corp., GenScript Biotech Corp., Hera Biolabs Inc., Illumina Inc., Intellia Therapeutics Inc., Merck KGaA, PerkinElmer Inc., Sangamo Therapeutics Inc., and Thermo Fisher Scientific Inc.

Market Dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Key Topics Covered:

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Website: www.technavio.com/

SOURCE Technavio

These press releases may also interest you

at 18:39
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Talis Biomedical Corporation pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued...

at 18:30
Think Research Corporation ("Think" or the "Company"), a company focused on transforming healthcare through digital health software solutions, announced today that it has engaged Oak Hill Financial Inc. ("Oak Hill") to provide communications and...

at 18:30
Pelangio Exploration Inc. ("Pelangio" or the "Company") is pleased to announce that it has entered into an earn-in letter agreement with 11530313 Canada Inc. ("Privco") on Pelangio's Gowan Project, located 16 km east of...

at 18:17
Peloton Interactive, Inc. provided a business update today and reported preliminary results for its second quarter Fiscal 2022 ended December 31, 2021....

at 18:05
Athersys, Inc. , an international, late-stage, regenerative medicine company, announced today the appointment of Daniel A. Camardo as the Company's Chief Executive Officer, effective February 14, 2022. Mr. Camardo is a senior pharmaceutical and...

at 17:44
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired...

News published on 29 november 2021 at 21:30 and distributed by: